Navigation Links
Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Date:8/19/2007

PLYMOUTH MEETING, Pa., Aug. 1 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported that development partner MedImmune, Inc. has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma. The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second Phase 2a study currently underway with the MAb, known as MEDI-528. Genaera and MedImmune entered into a collaborative licensing agreement for this program in 2001.

"This study begins another important step in evaluating the potential of the anti-IL-9 antibody as a new, long-term maintenance or controller therapy for symptomatic, persistent asthma," said Jack Armstrong, President and Chief Executive Officer of Genaera. "We are pleased that the anti-IL-9 antibody is progressing through MedImmune's respiratory inflammation pipeline and remain excited to be part of this partnership. Furthermore, we are optimistic that this study will add to the body of clinical and preclinical data supporting development of MEDI-528 as a potential therapy for this very serious and unfortunately all too common disease."

Two previous Phase 1 single-dose, dose-escalation studies have been conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. The antibody was well tolerated in both studies. MedImmune is also conducting an ongoing Phase 2a study, initiated in late 2006, to evaluate the efficacy of a single intravenous dose of MEDI-528 and its effect on disease mechanisms in adults with atopic asthma. Plans to initiate a
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- A decade-long JDRF-funded study led by the Institute ... Germany , is providing a deeper understanding of ... type 1 diabetes (T1D), highlighting the importance of pre-diabetes ... "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression ... The Journal of the American Medical Association . ...
(Date:6/19/2013)... LARKSPUR, Calif. , June 19, 2013 /PRNewswire/ ... to improve sample standardization and handling in many ... the issuance of new patents by the U.S. ... company,s thermo-conductive products developed to standardize sample handling ... accuracy of results in common laboratory procedures. ...
(Date:6/19/2013)... Md. , June 19, 2013 /PRNewswire/ -- Chindex ... an American healthcare company providing services in ... United Family Healthcare, a network of private hospitals ... opening of its Beijing United Family Rehabilitation Hospital ... projects of the United Family Healthcare ("UFH") network. ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5
... Ind., Nov. 1, 2010 Hill-Rom (NYSE: ... as Senior Vice President and Chief Financial Officer. Guinan ... and will officially join Hill-Rom on December 13, 2010. ... & Johnson, Guinan held a number of senior financial ...
... Romark Laboratories announced that data ... being presented at the 61st Annual Meeting of ... Diseases (AASLD), also known as The Liver Meeting® ... (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO) (Logo: ...
Cached Medicine Technology:Hill-Rom Appoints Mark Guinan as Chief Financial Officer 2Romark Announces Data Presented at AASLD Meeting 2010 2Romark Announces Data Presented at AASLD Meeting 2010 3Romark Announces Data Presented at AASLD Meeting 2010 4Romark Announces Data Presented at AASLD Meeting 2010 5
(Date:6/19/2013)... Leading Japanese pharmaceutical companies, along with the Japanese ... pledged their commitment to bolster Japan,s contribution to ... Fund (GHIT Fund), at a press conference held ... International Conference on African Development (TICAD V). , ... the Ministry of Health, Labour and Welfare, the ...
(Date:6/19/2013)... 19, 2013 Dental professionals are increasingly ... from minor to moderate sedation, a patient’s breathing depth ... Dentistry is the latest to update its guidelines to ... sedation in an effort to increase safety in procedures. ... Practice Act goes into effect July 1. , ...
(Date:6/19/2013)... 19, 2013 PREFERRED Therapy Providers, Inc. ... Arizona to offer a new Medicare Advantage Plan ... Paz, Yavapai and Mohave, Arizona counties. The agreement takes ... effective January 1, 2013 and Maricopa and Pima counties ... Inc., the parent company of WellCare of Arizona has ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... Scottsdale, AZ (PRWEB) June 19, 2013 Guests ... feel healthy, wealthy and wise even if they don’t go ... that does require some early thought. , ... pockets when they take advantage of the pet-friendly Scottsdale Paradise ... Percent Package . With at least 14 days advance notice, ...
Breaking Medicine News(10 mins):Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... COM , , VANCOUVER, Nov. ... COM) today disclosed that its Chairman and Chief Executive Officer, ... 45,000 common shares from his direct holding of Cardiome stock. ... to have been required to involuntarily sell any shares of ...
... the danger is about the same as using drugs ... News) -- Giving blood transfusions to treat anemia in ... clots, say University of Rochester, N.Y., researchers. , But ... cancer treatment-related anemia, the scientists said, after having analyzed ...
... Antonio Banderas launched his fifth,fragrance, BLUE SEDUCTION FOR ... City alongside cast members from Tony Award(R) Winning Best ... of the Roses, Ballet,Hispanico School of Dance, R. Evolucion ... (See video from PUIG USA at:, ...
... Nov. 28 Streamline Health Solutions,Inc. (Nasdaq: STRM ... quarter of fiscal year 2008 ended October 31, 2008 on ... and webcast to discuss,the results on Monday, December 15, at ... conference call to provide additional time for,completion of the necessary ...
... understanding of the disease generally, researchers say , , FRIDAY, ... people with the rarer, inherited form of Alzheimer,s disease ... understand the biology of the brain disorder. , ... a known genetic mutation causing the rare, early-onset form ...
... With new HIV infections outpacing the,number of people newly ... this World AIDS Day to call for a global commitment ... take place,on December 1st, in Washington, D.C., will be followed ... Given the recent election, the world is hopeful that ...
Cached Medicine News:Health News:Cardiome Discloses Chairman And CEO's Involuntary Share Sale 2Health News:Cardiome Discloses Chairman And CEO's Involuntary Share Sale 3Health News:Transfusing Anemic Cancer Patients Boosts Clot Risk 2Health News:Streamline Health Reschedules Q3 Financial Results Release and Conference Call for Monday, December 15, 2008 2Health News:Study Recruiting From Alzheimer's-Prone Families 2Health News:Faith and Civil Society Leaders Hold Interfaith Service to Commemorate World AIDS Day 2
... The Magnetom C! system features 270 accessibility ... with the smallest pole diameter available (54 ... of up to four coils, increased patient ... field strength is 0.35 Tesla. , ,The ...
... Quality of Vision and Contrast Sensitivity. ... illumination and glare luminance levels for ... testing with/without glare and background luminance ... ANSI standards. All Light Levels Microprocessor ...
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
STERILE VIEW Barrier Sleeves combine superior protection against contaminants with unsurpassed comfort and the convenience of universal sizing....
Medicine Products: